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SUMMARY 
 
This article presents a new method for predicting viral resistance to seven 
protease inhibitors from the HIV-1 genotype, and for identifying the positions in the 
protease gene at which the specific nature of the mutation affects resistance.  The neural 
network Analog ARTMAP predicts protease inhibitor resistance from viral genotypes.  A 
feature selection method detects genetic positions that contribute to resistance both alone 
and through interactions with other positions.  This method has identified positions 35, 
37, 62, and 77, where traditional feature selection methods have not detected a 
contribution to resistance. 
At several positions in the protease gene, mutations confer differing degrees of 
resistance, depending on the specific amino acid to which the sequence has mutated.  To 
find these positions, an Amino Acid Space is introduced to represent genes in a vector 
space that captures the functional similarity between amino acid pairs.   Feature selection 
identifies several new positions, including 36, 37, and 43, with amino acid-specific 
contributions to resistance.  Analog ARTMAP networks applied to inputs that represent 
specific amino acids at these positions perform better than networks that use only 
mutation locations.   
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1. Introduction 
 
A variety of treatment options are now available for patients infected with Human 
Immunodeficiency Virus (HIV).  Antiviral treatments may not lead to complete 
suppression of the virus, due to the rapid development of drug-resistant mutations in the 
viral genome.  For some patterns of mutations, the degree of resistance to some or all of 
the available antiviral drugs, including protease inhibitors, has been measured in vitro.  
These measurements can aid in the choice of antiviral treatment options against a viral 
subtype containing one of these patterns of mutations.  However, experimental testing to 
determine resistance values for all possible variants is combinatorially prohibitive.  For 
this reason, it is desirable to have some means of extrapolating from clinical assays to 
sequences for which the resistance value is unknown. 
The half-maximal inhibitory concentration (IC50) is a standard measure of drug 
effectiveness, equal (here) to the concentration required to reduce a viral count by 50%.  
The dimensionless Resistance Factor (RF) of a viral subtype to a given drug equals the 
IC50 value for the subtype divided by the IC50 value for a wild-type.  Stanford University 
maintains a publicly available database of the results of these assays 
(http://hivdb.stanford.edu/).  The database contains the RNA sequences coding for the 
protease enzymes of mutated varieties of the virus, together with the associated RF values 
of the viral subtypes to the seven protease inhibitors Nelfinavir (NFV), Saquinavir 
(SQV), Indinavir (IDV), Ritonavir (RTV), Amprenavir (APV), Lopinavir (LPV), and 
Atazanavir (ATV).   
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The neural network Analog ARTMAP and its accompanying feature selection 
method are here introduced and applied to the database of HIV-1 protease gene 
sequences.  Analog ARTMAP neural networks are trained on a subset of the data to 
produce a system capable of estimating the Resistance Factors of an arbitrary protease 
gene sequence to the seven protease inhibitors.  Feature selection methods are used to 
address two related questions: 
1)  At which positions do mutations in the protease gene contribute to resistance? 
2)  At which positions do the specific amino acids produced by mutations make 
different contributions to resistance?  
Each of these questions is addressed in two stages: hypothesis generation and 
hypothesis testing.  With regard to the first question, hypotheses are generated via feature 
selection from Analog ARTMAP networks trained on a subset of the data in which all 99 
positions in the protease gene are represented.  For each of the seven protease inhibitors, 
three position subsets that may contribute to resistance are considered.  The first subset 
includes all 99 positions in the gene.  The second subset is extracted from the literature, 
and includes positions that have been previously identified as possibly or definitely 
contributing to protease inhibitor resistance.  The third subset is a superset of the 
positions extracted from the literature, and also includes positions identified by Analog 
ARTMAP feature selection as being of equal or greater value to the prediction of 
resistance than any of the positions taken from the literature.   
With respect to the second question, hypotheses are generated by a measure of the 
gain in predictive utility of each position when the specific amino acid is considered vs. 
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when it is not.  This measure, called the Optimal Percent Correct Difference (OPCD), is 
used to generate two position subsets for each drug: the three positions with the greatest 
OPCD scores, and the positions with OPCD scores above 1%.  A third subset is 
composed of positions identified in the literature at which mutations possibly or 
definitely make a contribution to resistance depending on the specific amino acid.  In the 
fourth and fifth subsets, the specific amino acids are considered at every included 
position and at no positions, respectively.   
 Hypothesis testing for each question is accomplished by comparing the 
performance of Analog ARTMAP networks trained and tested on fifteen representations 
of the data for each drug.  These fifteen representations are created from the three 
protease gene position subsets times the five position subsets where specific amino acids 
are considered.  A new Amino Acid Space derived from the BLOSUM62 [1] protein 
scoring matrix represents positions at which specific amino acids are considered.   
 For each protease inhibitor, network performance on validation sets is used to 
select both the best position subset and the positions at which the specific amino acids are 
best taken into account.  Analysis of these position sets leads to an improvement in the 
network’s predictive accuracy over the default strategy of using the presence or absence 
of mutations at all 99 positions.  Improved accuracy ranges from 1.6% for Nelfinavir to 
11.9% for Atazanavir.  
This analysis identifies several positions in the protease gene not previously 
associated with resistance.  The nonlinearity of the genotype to Resistance Factor maps 
learned by Analog ARTMAP allows the feature selection method to identify positions at 
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which mutations contribute to resistance both directly and through interactions with 
mutations at other positions.  Mutual information independently evaluates the 
contribution to resistance made by each position in the protease gene.  Analog ARTMAP 
feature selection strongly implicates positions 35, 37, 62, and 77 for all seven protease 
inhibitors, while the low mutual information between these positions and Resistance 
Factors indicates that these are likely locations of accessory mutations which influence 
resistance only indirectly, through interactions with primary resistance conferring 
mutations. 
The analysis also highlights several positions in the protease gene not previously 
identified in the literature at which different mutations contribute different degrees of 
protease inhibitor resistance.  In particular, the mutations K43N, M36L, N37Q, and 
N37K are identified as likely contributors to hypersusceptibility for the protease 
inhibitors Saquinavir and Indinavir.   
 
2. HIV Protease Inhibitor Resistance: Preparation of the Data  
 
The data set consists of a list of protease gene sequences and, for each, the 
available Resistance Factors for each of the seven protease inhibitors for viral particles 
carrying the gene.  During preprocessing of the data, the RFs were replaced with their 
base 10 logarithms.  In cases in which different RFs were reported for the same 
sequences by different labs, the multiple entries in the database were replaced by a single 
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entry equal to the mean of the logarithms of the reported RFs.  Gene sequences with 
missing or ambiguous amino acids were discarded.   
The resultant data set consists of 725 unique protease genes.  Of these, 145 (20%) 
were chosen at random and kept in reserve to be used as the final test set, leaving 580 
sequences (80%) for training and validation. For many exemplars in the data set, the RF 
of a given protease gene has been reported relative to some but not all of the seven 
protease inhibitors.  For each drug, Table 1 shows the number of sequences for which 
RFs are known in the training/validation set, the test set, and the total.  Figure 1 shows 
the logarithmic histogram of RFs for each drug.  The vertical lines indicate the (log) 
cutoff values, defined as the clinically determined RFs above which treatment is not 
Number of Sequences per 
Laboratory of Origin  
Data Set Division Drug 
Viro-
Logic 
Only 
Virco 
Only 
Viro-
Logic and 
Virco 
Train/Val.  
(580 
Unique) 
Test 
(145 Unique) 
Total 
Number of 
Sequences 
(725 Unique) 
NFV 340 283 59 543 139 682 
SQV 337 294 21 519 133 652 
IDV 340 292 59 551 140 691 
RTV 322 294 59 540 135 675 
APV 290 212 22 422 102 524 
LPV 160 169 45 302 72 374 
ATV 59 11 43 91 22 113 
Table 1. Protease inhibitor resistance data: Number of sequences by 
laboratory of origin and division into training validation and test sets  
For each protease inhibitor, the table shows the number of gene sequences in 
the data set from each laboratory of origin, Virco and/or ViroLogic.  Where 
both labs have reported Resistance Factors for the same sequence, the 
logarithmic average of the two is used.  The number of sequences included in 
the reserved test set is also indicated.  The sequences in the train/validation set 
were further subdivided into training and validation sets for model parameter 
and representation selection independent of the test set.   
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Figure 1. Histograms of log10 Resistance Factors with cutoff values 
 For each of the seven protease inhibitors, dashed lines indicate the RF 
cutoff values above which each drug is considered ineffective. 
expected to succeed. The cutoff values used here are the average of the Virco 
Antivirogram and ViroLogic PhenoSense cutoff values: NFV: 3.25, SQV: 2.5, IDV: 2.75, 
RTV: 3, APV: 2.5, LPV: 3, and ATV: 3.   
The generalization from known protease gene RFs to unknown ones is 
accomplished by training an ensemble of Analog ARTMAP networks for each protease 
inhibitor.  Because each drug has its own learning system, the format in which the 
protease genes are encoded can be drug-specific.  For each drug, the encoding rests on 
two questions:  
1) At which positions do mutations influence drug resistance?  
2) For which positions is resistance influenced by the specific amino acid 
vs. simply the presence or absence of a deviation from the reference 
sequence?   
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Experimental evidence regarding these questions [2] provides a reference point for the 
computational approach introduced here. 
 
3. Adaptive Resonance Theory Neural Networks 
 
Adaptive Resonance Theory (ART) systems model real-time prediction, search, 
learning, and recognition. Unsupervised ART and supervised ARTMAP networks 
function both as models of human cognitive information processing [3-6] and as neural 
systems for technology transfer [7].  A neural computation central to both the scientific 
and the technological analyses is the ART matching rule [8], which models the interaction 
between top-down expectation and bottom-up input, thereby creating a focus of attention 
which, in turn, determines the nature of coded memories. 
Sites of early and ongoing transfer of ART-based technologies include industrial 
venues such as the Boeing Corporation [9] and government venues such as MIT Lincoln 
Laboratory [10].  Design principles derived from scientific analyses and design 
constraints imposed by targeted applications have jointly guided the development of 
many variants of the basic networks, including fuzzy ARTMAP [11], ART-EMAP [12], 
ARTMAP-IC [13], Gaussian ARTMAP [14], and distributed ARTMAP [15].  
Comparative analysis of these systems has led to the identification of a default ARTMAP 
network, which features simplicity of design and robust performance in many application 
domains [16].  Analog ARTMAP extends the capabilities of the default system while 
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retaining its simplicity and a priori parameter specifications.  Appendix A includes a 
self-contained Analog ARTMAP algorithm. 
 
3.1 Default ARTMAP 
 
The default ARTMAP algorithm outlines a procedure for labeling an arbitrary 
number of output classes in a supervised learning problem. A critical aspect of this 
algorithm is the distributed nature of its internal code representation, which produces 
continuous-valued test set predictions distributed across output classes.  ARTMAP 
variants with winner-take-all (WTA) coding and categorical predictions have, by 
comparison, been consistently less successful with respect to labeling accuracy and post-
processing adjustment capabilities. 
ARTMAP’s capacity for fast learning implies that the system can incorporate 
information from examples that are important but infrequent, and can be trained 
incrementally.  Fast learning also causes each network’s memory to vary with the order 
of input presentation during training. Voting across several networks trained with 
different orderings of a given input set takes advantage of this feature, typically 
improving performance and reducing variability as well as providing a measure of 
confidence in each prediction [11]. While the number of voting systems is, in general, a 
free parameter, five voters have proven to be sufficient for many applications. Default 
ARTMAP thus trains five voting networks for each training set combination.   
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Even with the number of voters fixed, other design choices appear in systems 
where output activations may be distributed. In particular, default ARTMAP, which 
produces a continuous-valued distribution 
k
!  across output classes k for each test set 
item, presents options for combining weighted predictions across voters to make a final 
class choice. One strategy sums the 
k
!  values of individual networks to produce a net 
distributed output pattern, which is then used to determine the predicted class. An 
alternative strategy first lets each voting network choose its own winning output class, 
then assigns the test set inputs on the basis of these individual votes. In most applications, 
the first of these two voting strategies produces better results.  
 
3.4 Analog ARTMAP 
 
Previous applications of ART neural networks to genetic databases [17-19] have 
demonstrated the efficacy of this family of neural networks on unsupervised learning (or 
clustering) problems in genetics.  Because the prediction of protease inhibitor resistance 
is a supervised learning problem, the specific ART network architectures used in these 
applications are not sufficient.   
Prediction of resistance can be framed as a classification problem, where the two 
class labels, drug-resistant and drug-susceptible, are assigned to each HIV protease gene 
by dichotomizing the RFs as above or below their cutoff values.  An accurate prediction 
of susceptibility to a particular protease inhibitor would indicate whether treatment with 
that drug would be likely to produce an effective suppression of viral load.  However, this  
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prediction scheme would be insufficient to determine which protease inhibitors are likely 
to be most effective for a given patient.  To accomplish this it is necessary to know the 
degree of resistance a particular viral subtype would have against each of the protease 
inhibitors, so that the drug to which the viral subtype is least resistant can be identified.  
A computational system that learns accurate associations between inputs (gene 
sequences) and continuous-valued outputs (Resistance Factors) would accomplish this 
task.  Analog ARTMAP (Appendix A), a neural network that extends default ARTMAP 
to make continuous predictions, is designed for this purpose.    
 
3.5 ARTMAP Feature Selection 
 
 When Analog ARTMAP is applied to the problem of predicting protease inhibitor 
resistance from gene sequences, the network learns patterns of interdependencies among 
mutations at various locations in the genes.  Post-training analysis of the weights learned 
by the network reveals these patterns, as well as giving insight into the contribution to 
protease inhibitor resistance made by specific mutations at each position in the gene.  The 
feature selection method described below builds on a method that has been applied to 
other ARTMAP networks [7].    
 ARTMAP networks learn from complement-coded inputs, which allow the system 
to code features that are consistently absent, as well as those that are consistently present, 
with respect to each coded category J.  That is, a given M-dimensional vector a!  in the  
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data set is preprocessed to produce a 2M-dimensional input vector ),( Caa !!
!
!A , 
where )1(
i
C
i
aa !" .  
ARTMAP networks dynamically add committed nodes as needed during training 
(Appendix A).  The weights associated with these nodes are given a geometric 
interpretation [11] as coding boxes that define rectangular regions in the M-dimensional 
input feature space (Figure 2).  If the weight vector associated with coding node J is wJ 
),...,,,,...,,( ,2,2,1,,2,1 JMJMJMJMJJ wwwwww ++= , then the two opposing corners of coding 
box J are defined by the vectors ),...,,( ,,2,1 JMJJ www  and ),...,,( ,2,2,1
C
JM
C
JM
C
JM
www
++
, 
corresponding to the complement-coded input vector.  Each coding node in an Analog 
ARTMAP network also has a continuous-valued output weight (WJk) for each component 
Figure 2.  Feature selection method for Analog ARTMAP 
Analysis of the weights learned by an Analog ARTMAP network indicates which 
input components are most useful for output predictions.  The value assigned to 
each input component reflects the contribution made by that component both 
independently and through interactions with other input components.  The ratio in 
the feature selection measure (Equation 1), equal to (a+b)/(1-(c+d)) in the 
diagram, would increase if the two boxes separated, and drops to zero when the 
boxes are identical  in dimension i. 
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k of the output space, and an instance counting weight (cJ) which tracks the number of 
input vectors associated with the coding node J.   
Feature selection is accomplished by assigning a value to each component i of the 
input space that quantifies the utility of feature i for the prediction of output component k 
via the equation: 
       (1) 
where !  denotes fuzzy intersection, or component-wise minimum.  The ratio in 
Equation 1 measures the degree of overlap of the projections of coding boxes j and J 
onto input dimension i (Figure 2).  The ratio equals zero when the two boxes overlap 
fully, labeling feature i as of no value in differentiating output dimension k.  The ratio is 
greater than 1 when the two boxes do not overlap at all, and are therefore of great value.      
In the application of Analog ARTMAP to the prediction of protease inhibitor 
resistance, the output spaces (Resistance Factors) are one-dimensional, so the index k 
drops out of Equation 1, and each dimension of the input space is characterized by a 
single ∆ value.  
 
4. Locating Positions in the Protease Gene at which Mutations Affect Drug 
Resistance 
 
  The clinically important question: 
At which positions in the protease gene are mutations indicative of protease 
inhibitor resistance?  
( ) ( )!" ++
++
#
#
$
%
&
&
'
(
)*)*
*+*
*=+
JjJ jiJijMiJMi
jiJijMiJMi
jkJkjJ
wwww
wwww
WWccik
, ,,,,
,,,,
1
)|(
CAS/CNS Technical Report TR-2007-004 
 
15 
is addressed through feature selection from trained Analog ARTMAP networks.  The 
results of this feature selection method are compared with the mutual information profiles 
(Section 4.1) of the gene; the marginal utility, or optimal percent correct (Section 4.2), 
for each position; and the experimental findings as summarized in the clinical literature.  
Figure 3(a-d) shows resistance profiles for each of the seven protease inhibitors 
calculated with four methods, as follows.   
The resistance profiles produced by each of the four computational methods 
convey different information about the contributions to protease inhibitor resistance made 
by mutations at specific positions in the protease gene.  Mutual information profiles 
select features that contribute to protease inhibitor resistance directly, rather than through 
interactions with mutations at other positions.  When dichotomized RFs are used (Figure 
3a), the profiles provide a measure of the degree to which mutations at each position 
contribute to the development of sufficient protease inhibitor resistance to cause 
treatment failure.  When the RFs themselves are used to generate the mutual information 
profiles (Figure 3b), the profiles indicate the overall contribution to resistance of 
mutations at each position, but irrespective of whether that contribution is near its RF 
cutoff value.  The Optimal Percent Correct (OPC) and Optimal Percent Correct 
Difference (OPCD) score profiles (Figure 3c) help determine which positions contribute 
differentially to resistance depending on the specific amino acids to which they mutate.  
The Analog ARTMAP feature selection values (Figure 3d) select features that contribute 
to resistance both directly, and through interactions with mutations at other positions.  
Combinations of mutual information profiles and Analog ARTMAP feature selection ∆  
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Figure 3a. Mutual information between 
binary representations of mutation locations 
and Resistance Factors (RFs) dichotomized at 
the cutoff values 
Resistance profiles of seven Protease Inhibitors 
are estimated by taking the mutual information 
(MI) between binary representations of 
mutations in gene sequences and their 
corresponding RFs dichotomized into resistant 
and susceptible bins.  Mutations at positions 
with high MI scores are likely to be primary 
mutations. 
 
Figure 3b. Mutual information between 
binary representations of mutation locations 
and continuous Resistance Factors   
Resistance profiles are estimated by taking the 
mutual information between binary 
representations of mutations in gene sequences 
and their corresponding RFs.     
Figure 3c. OPC scores   
Resistance profiles are estimated by calculation of the 
Optimal Percent Correct (OPC) scores for each 
position.  OPC scores are shown as solid bars for the 
binary representation of the data.  Empty bars show 
the OPC score for each position when the specific 
amino acids are taken into account.  Optimal Percent 
Correct Difference (OPCD) scores are defined by 
subtracting the binary OPC score from the OPC score 
found by taking into account the specific amino acids 
for each position.  The OPCD scores are non-negative. 
Figure 3d. Analog ARTMAP feature selection 
results   
Resistance profiles are estimated by applying feature 
selection to Analog ARTMAP networks trained on 
binary representations of the data.  Mutations at 
positions with high values may be either primary or 
accessory. 
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values (Equation 1) not only identify mutations that contribute to protease inhibitor 
resistance, but provide a means for distinguishing between primary mutations which 
contribute to resistance directly (e.g., at positions 48 and 90) and accessory mutations 
which contribute to resistance through interactions with other positions (e.g., at positions 
35 and 77).     
 
4.1 Mutual Information Profiles 
 
Mutual information (MI) [20] provides a means of evaluating the contribution of 
mutations at individual positions in the protease gene to protease inhibitor resistance.  As 
applied here, MI evaluates each position in the gene independently.  As a result, this 
method tends to give higher values to primary than to accessory mutations.   
The mutual information between two variables gives a measure of how much the 
uncertainty in one is reduced by knowledge of the other, with a value of zero when the 
two variables are statistically independent.  The mutual information between the variables 
X and Y is defined as  
             (2) 
where p(X) and p(Y) denote the probability distributions of X and Y respectively, p(X,Y) is 
the joint distribution of the variables, and ( , )p X YE  is the expectation operator taken over 
all possible values of X and Y.   
Figure 3a shows the mutual information between the dichotomized RFs (binned 
according to the cutoff values listed in Section 2), and the individual positions in the 
!!
"
#
$$
%
&
=
)()(
),(
log),( 2),(
YpXp
YXp
EYXMI YXp
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protease gene represented as binary vectors indicating the presence or absence of a 
mutation at each location.  Figure 3b shows the mutual information between this binary 
representation of the gene positions and the analog RFs.  The mutual information 
between the binary representation and the dichotomized RFs (Figure 3a) would identify 
the mutations that are likely to produce RFs greater than the cutoff value, and are 
therefore crucial for determining the likelihood of treatment success.  The mutual 
information between the binary representation and the analog RFs, on the other hand, 
identifies the positions that are indicative of the greatest changes in resistance.  These two 
kinds of mutual information profiles highlight the differences between selecting the 
features that are most relevant to classifying the genes as resistant or susceptible vs. 
finding the features that are most useful for predicting the RFs themselves.  For many 
patients, finding a drug that will lead to successful management of the viral population is 
the essential issue, and so determining whether a particular viral strain is susceptible to a 
given drug motivates the investigation of the individual positions in the gene.  For others, 
especially those who have developed multi-drug-resistant strains of the virus, finding the 
drug to which a given strain is least resistant becomes more important, and so the 
emphasis of the investigation shifts to the relative magnitude of conferred resistance.  
 
4.2 Optimal Percent Correct Scores  
 
A second means of evaluating the positions in the protease gene individually is 
the Optimal Percent Correct (OPC) score.  When RFs are dichotomized as resistant or 
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susceptible, the relative utility of an individual position can be evaluated by looking at 
the percent correct of the best prediction that could be made on the basis of that feature 
alone.  This measure is an estimate of the (complement of the) Bayes Error Rate [20] 
from sample data.  The explicit calculation of a Bayes Error Rate requires knowledge of 
the underlying probability distributions for each class.  The OPC score is equivalent to 
one minus the Bayes Error Rate when the true distribution is assumed equal to the sample 
distribution.   
With respect to a specific protease inhibitor, each position i in the sequence is 
either wild-type or mutated in the binary representation; and a given gene sequence is 
either resistant or susceptible.  Accordingly, given only the information that the sequence 
is wild-type at position i, the best possible outcome would predict resistant or susceptible 
according to which is more represented among position i wild-types in the training set.  
Similarly, given only the information that the sequence is mutated at position i, the 
optimal outcome would predict resistant or susceptible according to which is more 
represented among position i mutations in the training set.  Thus the binary OPC score for 
position i relative to the protease inhibitor is given by the equation: 
   (3) 
where N is the number of sequences for which RFs are known, WR is the number of 
resistant sequences that are wild-type at position i, WS is the number of susceptible 
sequences that are wild-type at position i, MR is the number of resistant sequences that 
contain a mutation at position i, and MS is the number of susceptible sequences that 
contain a mutation at position i.  Note that WR + WS + MR + MS = N. 
( )},max{},max{
1
MSMRWSWR
N
OPCBinary +=
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Figure 3c shows the OPC scores for each of the positions in the protease gene 
relative to each of the seven protease inhibitors in the data set.  This simple measure 
gives some indication of which positions are predictive of resistance, but fails to take into 
account interactions among mutations at multiple positions.  Section 5 details the use of 
OPC scores to measure the predictive gain when the specific amino acid found at a given 
position is taken into account. 
 
4.3 Analog ARTMAP Feature Selection Results 
 
Figure 3d shows the feature selection results for ARTMAP networks trained on a 
binary representation of the protease inhibitor data with all 99 positions included.  
Validation was used to select the values of the parameter 
a
!  that lead to the best 
performance for each drug.  For each drug, 25 networks were trained on 2/3 of the 
training data, using the fixed parameter values 2.0=
b
! , 13=Q , and 01.0=!  
determined from pilot studies.  Parameter 
a
!  values for each drug were determined 
through validation (Table 2).  Features were selected from the trained networks 
(Equation 1), and the averaged results are presented.  The Analog ARTMAP feature 
selection profiles differ noticeably from the mutual information and optimal percent 
correct profiles presented in Figures 3a-c.  This reflects the difference between the global 
nature of the Analog ARTMAP feature selection process, which considers each genome 
as a whole, taking possible feature interactions into account; and the local approach to  
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feature selection employed by the mutual information and optimal percent correct 
methods, which consider individual gene locations in isolation. 
 
4.4 Feature Selection Results Relative to Protease Gene Position Sets Described 
in the Literature   
 
Analysis of the individual positions in the protease gene has been presented in the 
literature from both experimental [2,21] and numerical [22] perspectives.  These 
descriptions provide a basis for comparison and discussion of the feature selection results 
presented here.  The second column of Table 3 lists a set of positions with known or 
suspected contributions to resistance for each of the protease inhibitors under 
consideration.  For each drug, the results of feature selection from trained Analog 
ARTMAP networks are used to produce a Minimal SuperSet (MSS) of this list by 
including all of the positions given a ∆ value (Equation 1) greater than or equal to the 
lowest scoring position in the list.  The resultant position sets are given in the third 
column of Table 3.  Figure 4 shows the 99 positions in the protease gene ranked by the ∆ 
  
Drug NFV SQV IDV RTV APV LPV ATV 
a
!  0.97 0.97 0.91 0.97 0.95 0.97 0.95 
Table 2. Vigilance baseline (
a
! ) parameter values used for feature 
selection 
Validation was used to select the values of 
a
!  for a binary representation 
of all 99 positions in the protease gene for each drug.  These values were 
used to train networks for feature selection.   
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Protease 
Inhibitor 
Rank order of positions 
Previously Associated with 
Resistance (PAR) 
Rank order of Minimal 
SuperSet (MSS) of PAR 
positions 
NFV 10,71,90,46,93,36,77,82,54,20,88, 
84,63,73,30,53,48,50 
 
10,71,90,46,93,36,35,77,82,54,62, 
37,20,64,41,13,88,84,63,15,57,73, 
30,72,19,12,14,69,60,33,24,70,61, 
74,45,32,58,53,48,50 
SQV 10,90,71,46,54,93,82,36,84,20,73, 
63,48,53,50 
 
10,90,71,46,54,93,82,36,77,35,62, 
84,37,20,64,41,13,73,88,57,72,15, 
63,30,12,19,48,33,14,60,24,69,32, 
53,61,47,45,74,70,43,89,67,55,85, 
16,58,23,50 
IDV 10,71,90,46,82,93,54,36,20,84,73, 
63,88,33,24,48,32,53,50,47 
10,71,90,46,82,93,54,77,36,62,35, 
37,64,41,20,84,13,73,63,57,72,15, 
88,30,14,12,60,19,33,24,69,70,48, 
61,74,32,45,53,43,58,85,67,89,50, 
55,47 
RTV 10,71,82,90,54,46,93,36,84,20,63, 
88,73,33,32,48,53,47,50 
10,71,82,90,54,46,93,36,77,62,35, 
37,84,64,20,41,13,57,63,15,88,73, 
72,30,12,14,19,33,60,24,69,70,32, 
61,48,45,53,74,47,43,58,85,89,50 
APV 10,46,71,90,54,93,82,36,84,88,20, 
63,73,33,32,47,50,53,48 
 
10,46,71,90,54,93,82,77,36,62,84, 
35,37,88,20,64,13,63,41,57,73,15, 
72,30,33,19,12,14,60,24,69,32,74, 
47,50,70,53,89,61,45,55,16,76,58, 
48 
LPV 10,71,54,82,46,90,93,36,84,20,73, 
63,88,24,33,53,32,48,47,50 
10,71,54,82,46,90,93,36,77,62,35, 
37,84,64,20,41,13,15,72,73,63,57, 
88,14,24,12,19,30,33,60,61,69,53, 
70,74,32,48,76,47,43,16,55,85,18, 
89,45,58,67,39,50 
ATV 71,10,36,93,90,82,20,46,54,88,63, 
33,50,73,32,84,47,53,24,48 
71,10,36,35,13,93,90,77,62,82,37, 
30,20,41,46,64,54,88,63,69,33,14, 
12,70,50,15,73,57,89,32,84,45,19, 
60,47,16,66,53,58,72,24,85,61,4, 
43,23,79,65,34,11,2,8,48 
 
 
 
 
 
 
 
Table 3. Positions Previously Associated with Resistance (PAR) and 
Minimal SuperSet (MSS) positions ranked by Analog ARTMAP feature 
selection values 
 Protease gene positions are ranked according to Analog ARTMAP feature 
selection ∆ values.  Column two shows the ranking attributed to the positions 
previously associated with resistance.  Column three shows the ranking of the 
MSS positions, with positions not previously associated with resistance in bold 
face.  Note that for all seven drugs, the majority of the highly ranked MSS 
positions are positions previously associated with resistance, and were 
correctly identified by the feature selection procedure without the 
incorporation of prior knowledge. 
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Figure 4. Positions in the protease gene  
ranked according to Analog ARTMAP 
feature selection ∆ values 
The 99 positions in the gene are ranked 
according to their average ∆ values, plotted 
above the abscissa.  Bars beneath the abscissa 
indicate the positions previously associated 
with resistance (PAR), many of which are 
clustered near the high end of the rankings.  
The method corroborates existing knowledge 
and identifies several candidate positions not 
previously associated with resistance.     
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values assigned to them in Analog ARTMAP feature selection.  Bars beneath the abscissa 
indicate positions with previously known or suspected contributions to resistance. 
 
5. Locating Positions in the Protease Gene at which Resistance is Differentially 
Influenced by Specific Amino Acids  
 
 In addition to the question of which positions in the protease gene contribute to 
resistance, it is also useful to know which positions contribute to resistance differentially 
depending on the specific amino acid present in the mutation.  Feature selection methods 
are brought to bear on this problem by comparing feature selection values for each 
position when the specific amino acid present in the mutation is considered vs. when it is 
not.  The positions with the greatest increase in feature selection values are the identified 
candidates for an amino acid-specific effect on resistance. 
 
5.1 Optimal Percent Correct Difference Scores 
 
 The OPC scores (Section 4.2) can extended to measure the relative utility of 
taking into account the specific amino acid to which a given position has mutated vs. 
considering only whether or not the position contains a mutation.  The binary OPC score 
for position i, calculated only from the presence or absence of a mutation at this position, 
is plotted as solid bars in Figure 3c.  The analog OPC score reflects the optimal  
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Table 4. The 10 positions with highest OPCD scores for each drug 
Positions in the protease gene are ranked according to their OPCD scores for 
each drug.  Each box lists the position and the corresponding OPCD score in 
parentheses.  Mutations at positions with high OPCD scores are likely to 
contribute differentially to resistance depending on the specific amino acids 
found there. 
 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 
NFV 63 
(2.2%) 
12 
(1.3%) 
37 
(0.9%) 
36 
(0.6%) 
54 
(0.4%) 
82 
(0.3%) 
69 
(0.3%) 
67 
(0.3%) 
59 
(0.3%) 
34 
(0.3%) 
SQV 71 
(1.8%) 
82 
(1.5%) 
43 
(1.2%) 
33 
(1.1%) 
72 
(0.8%) 
67 
(0.8%) 
89 
(0.6%) 
74 
(0.6%) 
10 
(0.6%) 
79 
(0.5%) 
IDV 37 
(4.2%) 
63 
(4.1%) 
88 
(2.5%) 
82 
(1.3%) 
36 
(1.2%) 
12 
(1.0%) 
33 
(0.9%) 
47 
(0.7%) 
43 
(0.6%) 
54 
(0.4%) 
RTV 37 
(3.9%) 
63 
(2.8%) 
33 
(1.2%) 
36 
(1.2%) 
72 
(0.9%) 
12 
(0.7%) 
47 
(0.7%) 
43 
(0.6%) 
20 
(0.6%) 
88 
(0.4%) 
APV 71 
(5.0%) 
50 
(1.9%) 
72 
(1.0%) 
82 
(0.8%) 
37 
(0.8%) 
20 
(0.8%) 
33 
(0.6%) 
88 
(0.6%) 
70 
(0.6%) 
67 
(0.6%) 
LPV 71 
(4.5%) 
54 
(1.9%) 
82 
(1.6%) 
72 
(1.1%) 
88 
(0.8%) 
63 
(0.8%) 
37 
(0.8%) 
20 
(0.8%) 
73 
(0.8%) 
43 
(0.8%) 
ATV 45 
(3.5%) 
37 
(2.7%) 
69 
(1.8%) 
89 
(0.9%) 
70 
(0.9%) 
63 
(0.9%) 
19 
(0.9%) 
47 
(0.9%) 
46 
(0.9%) 
10 
(0.9%) 
prediction that could be made when the particular amino acids produced by mutations at 
position i are considered: 
 (4) 
where Φ is the set of non-wild-type amino acids found at position i.  These values are 
plotted as empty bars in Figure 3c.  The Optimal Percent Correct Difference (OPCD) 
score equals the difference between the two OPC scores: 
(5) 
The OPCD provides a simple measure of the utility of distinguishing among amino acids 
at each location in the protease gene. 
Ranking the positions by the amount of predictive accuracy gained by considering 
the specific amino acid gives an indication of which positions should be given an Amino 
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Acid Space representation in the classification of complete sequences.  Table 4 lists the 
10 positions with the greatest gain for each drug. 
 
6. Representing Genetic Sequences for Machine Learning Applications 
 
The application of a machine learning technique (clustering, classification, or 
regression) to databases of genetic samples requires a decision as to how the genes will 
be represented as vectors.  The appropriate choice of representational scheme depends on 
the problem.  For example, genes can be represented as a set of entries corresponding to 
the physical or chemical properties of each of the amino acids encoded by the gene [23].  
This may be useful in situations where there is prior knowledge indicating that specific 
physical or chemical amino acid properties are likely to be critical.   
When the class of a given genetic sequence is hypothesized to be determined 
entirely by the positions at which it differs from a reference sequence, each sequence can 
be represented as a binary string, with a value of one indicating where an amino acid in 
the chain differs from the reference sequence.  This binary representation has the 
advantage of low dimensionality, and typically requires fewer gene sequences to 
represent the input space.  In instances where the phenotypic category of a gene sequence 
depends critically on which amino acid is found at a given position, a new input 
representation is required.  
In an application of Self Organizing Feature Maps to the prediction of protease 
inhibitor resistance, Drăghici and Potter [24] assign a single dimension to each amino 
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acid in the protease enzyme.  In this approach, a position not containing a mutation is 
represented with a zero. The N mutations found at a given position are ranked by 
frequency of occurrence, and assigned values 1/N, 2/N, …,1, with the most common 
mutation assigned a value of 1/N, and the least common a value of 1. This 
representational scheme has the advantage of taking into consideration the specific amino 
acids in the mutated sequences, but it does not allow for a natural generalization to novel 
strings that contain a residue at a given position not found in the training set.      
In other machine learning applications [25,26] each position in the gene is 
represented with an indicator vector, in which each of the twenty amino acids is encoded 
as a 20-dimensional vector of 19 zeros and a single one.  The location of the one in the 
vector indicates the identity of the amino acid found at that position in the gene.  Some 
gene sequences have loci at which mixtures of amino acids have been reported, resulting 
either from ambiguous measurement or the presence of significant quantities of 
genetically distinct viral subtypes in the clinical sample.  Representing genes with 
indicator vectors has the advantage that loci at which mixtures are reported have a natural 
representation as the sum of the indicator vectors that represent the amino acids in the 
mixture.  However, indicator vectors have the disadvantage that by representing the set of 
amino acids with mutually orthogonal vectors, a machine learning system cannot 
meaningfully extrapolate to genes containing an amino acid not found at the 
corresponding position in any of the training sequences.  Furthermore, the computational 
requirements are significantly increased by the use of 20 dimensions for each position 
included in the representation.       
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 A novel means of representing gene sequences introduced here combines low 
dimensionality (eight dimensions per position) with a meaningful metric.  This Amino 
Acid Space applies methods developed for gene sequence alignment in such a way that 
the pairwise functional similarity of amino acids is a decreasing function of the pairwise 
distances of vectors representing them.  The Amino Acid Space representation is used to 
test hypotheses about individual positions in the protease gene and the contribution to 
protease inhibitor resistance of specific mutations found at these positions. 
 
6.1 Amino Acid Spaces 
 
Protein scoring matrices such as BLOSUM (BLOcks SUbstitution Matrix) [1] and 
PAM (Percent Accepted Mutations) [27] assign numerical values to the pairwise 
functional similarities between amino acids.  Both PAM and BLOSUM matrices are 
typically used for sequence alignment, but the pairwise similarity measures they contain 
can also be used to construct Amino Acid Spaces that incorporate this information. 
The construction of an Amino Acid Space from a scoring matrix proceeds in two 
stages.  A 20x20 matrix of pairwise dissimilarities ( ijD ) is first generated by applying a 
monotonically decreasing function to the off-diagonal elements of a scoring matrix: 
          (6) 
where ijS  is the pairwise similarity score assigned to amino acids i and j from the scoring 
matrix, and B is a constant described below.  
 
2/ijS
ij BD
!
=
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Multidimensional scaling (MDS) [28] is a procedure for finding a set of vectors 
such that the pairwise distances between vectors are as close as possible (squared error) 
to the pairwise dissimilarities in a target dissimilarity matrix.  By applying MDS to the 
dissimilarity matrix Dij in Equation 6, an Amino Acid Space can be created in which the 
pairwise distances between the vectors representing individual amino acids closely 
approximate the functional dissimilarities between amino acids expressed in a protein 
scoring matrix.  The computational criterion is to preserve the order of functional 
proximity between each amino acid and all others.   
 The following computations show how an Amino Acid Space may capture the 
ordinal relations among amino acids expressed in the BLOSUM62 protein scoring 
A           (Alanine) 0.3226 0.2079 0.4769 0.4752 0.1195 0.3778 0.3334 0.4406 
C         (Cysteine) 0.5103 0.5356 0.5294 0.4992 0.0477 0.4720 0.5033 0 
D (Aspartic Acid) 0.4525 0.4454 0.3476 0 0.3963 0.7650 0.3349 0.7400 
E (Glutamic Acid) 0.5469 0.2189 0.2986 0.1833 0.5400 0.5847 0.1463 0.7723 
F (Phenylalanine) 0.8412 0.6857 0.3989 0.3895 0.2832 0.0601 0.2232 0.3589 
G           (Glycine) 0 0.5097 0.4953 0.2775 0.4266 0.3566 0.3396 0.5876 
H         (Histidine) 0.5508 0.6261 0 0.3082 0.5620 0.4497 0.2171 0.5218 
I        (Isoleucine) 1.0000 0.3639 0.4627 0.4680 0 0.3557 0.3884 0.3896 
K             (Lysine) 0.4673 0.1867 0.2228 0.4631 0.4300 0.7142 0 0.4657 
L           (Leucine) 0.9120 0.2890 0.4555 0.7441 0.2262 0.3178 0.2877 0.2596 
M     (Methionine) 0.8427 0.2745 0.5632 0.4674 0.3884 0.4276 0.1651 0.2193 
N     (Asparagine) 0.4127 0.6141 0.2654 0.4319 0.4630 0.7654 0.3016 0.7279 
P            (Proline) 0.3904 0 0.2040 0.1989 0.4092 0.6895 0.5794 0.3818 
Q       (Glutamine) 0.5742 0.2763 0.3962 0.2809 0.7199 0.6319 0.1589 0.4439 
R          (Arginine) 0.4478 0.2906 0.2317 0.7046 0.6370 0.5997 0.1253 0.5435 
S              (Serine) 0.3749 0.4898 0.5432 0.3524 0.2555 0.7065 0.2431 0.4750 
T        (Threonine) 0.6056 0.3971 0.5577 0.5198 0.3935 0.6031 0.6055 0.5391 
V              (Valine) 0.8460 0.1277 0.5021 0.3902 0.1221 0.2857 0.4667 0.4176 
W    (Tryptophan) 0.6056 0.6393 0.4773 0.3571 0.6563 0 0.2649 0.1267 
Y          (Tyrosine) 0.7632 0.6023 0.1604 0.3436 0.4790 0.1580 0.2693 0.3056 
Table 5. An eight-dimensional Amino Acid Space that preserves 
the ordinal relations of the BLOSUM62 protein scoring matrix 
By encoding amino acids with the corresponding eight-dimensional 
vector, genes can be represented in a space with a metric that reflects 
the functional similarities among amino acids.   
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matrix.  First, for an amino acid },...,,{ YCA!" , rank the amino acids by their similarity 
to α according to the scoring matrix.  Second, rank the amino acids by their distance to α 
in the Amino Acid Space.  Because of ties in the orderings, these two rankings are maps 
from the set of amino acids to a partition ! of the integers 1…20:    
(7) 
 (8) 
Each map assigns to each amino acid the set of positions in the ranking for which it is 
tied.  The discordance D~  between the two rankings 1
!
O  and 2
!
O is then measured by: 
                 (9) 
where  
(10) 
Finally, a measure of the overall difference D between the ordinal relations of the scoring 
matrix and the Amino Acid Space is given by: 
     (11) 
The parameter B in Equation 6 can be varied to produce an Amino Acid Space 
which will reduce D in Equation 11 to 0.  Dissimilarity matrices are calculated from the 
BLOSUM62 matrix via Equation 6 using values of B ranging from 1 to 2 in increments 
of 10-4.  For each of these dissimilarity matrices, MDS is applied to produce 19 Amino 
Acid Spaces of dimension 1, 2, …, 19.  Calculation of the D values for each of these 
Amino Acid Spaces via Equation 11 shows that the lowest dimensional Amino Acid 
Space for which D goes to 0 is produced when B = 1.1966.  In this case, the  
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corresponding Amino Acid Space perfectly captures the ordinal relations between the 
amino acids as expressed in the BLOSUM62 matrix in just eight dimensions (Table 5). 
 
7. Using the Results of Feature Selection to Enhance the Prediction of Protease 
Inhibitor Resistance 
 
 Combining the results of selecting a subset of protease gene positions for 
inclusion, and further of selecting a subset to be given an Amino Acid Space 
representation, produces a set of testable hypotheses.  For each drug, 15 representations 
are compared.  Three sets of included positions are tested:  
  1) The complete set of positions 1-99 (All)  
 2) The positions previously associated with resistance (PAR, Table 3)  
 3) The drug-specific Minimal SuperSet (MSS) of these positions identified  
 by Analog ARTMAP (Section 4.4)   
 
Protease Inhibitor OPCD Best Three OPCD > 1% 
NFV 12,37,63 12,63 
SQV  43,71,82 33,43,71,82 
IDV  37,63,88 12,36,37,63,82,88 
RTV  33,37,63 33,36,37,63 
APV  50,71,72 50,71 
LPV  54,71,82 54,71,72,82 
ATV  37,45,69 37,45,69 
Table 6. Two Position subsets given an Amino Acid Space representation in 
trials 
Column 2 lists the three positions with the highest OPCD scores for each drug.  
Column 3 lists all the positions with OPCD scores greater than 1% 
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For each of these sets of included positions, five sets of positions are given an Amino 
Acid Space representation:  
  1) All of the included positions (All AA)  
  2) No positions (All Binary)  
  3) The set of positions with scores greater than 1% (OPCD>1%) (Table 6) 
   4) The three positions with the highest scores (OPCD3) (Table 6) 
  5) The positions 33, 46, 47, 50, 54, 63, 71, 82, 88, and 93, at which  
  the specific amino acids may contribute differentially to resistance  
  (AAPAR) according to the results summarized in the literature [2] 
 Positions given an Amino Acid Space representation are assigned values equal to 
1/8 of the corresponding row of Table 5.  This ensures that the L1 distance between two 
gene sequences that differ at one position is at most one, irrespective of whether that 
position is given a binary or an Amino Acid Space representation. 
 Figure 5 shows the performance of networks trained on the fifteen 
representations for each of the seven protease inhibitors.  For each drug and 
representation, the mean correlation coefficient between the predicted and the target 
values of the log Resistance Factors is calculated for five divisions of the data into  
Protease 
Inhibitor 
Representation 
a
!  
Correlation Coefficient 
between Predicted and 
Actual RFs  
Figure 5. Comparison of network performance on validation sets for fifteen 
representational schemes per drug 
For each drug, and for each of the fifteen representations, five voter ensembles of 
five networks each were trained with 2/3 of the train/validation data and tested 
on the remaining 1/3 for every value of 
a
!  in the set {0.81,0.83,…,0.99}.  For 
each drug and representation, the value of 
a
!  that led to the highest average 
correlation coefficient between prediction and ground truth on the validation set 
was chosen.  
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training and validation sets.  For each division, an ensemble of voters was constructed by 
training five networks with randomly chosen orderings of the training set, using the fixed 
parameter values 01.0=! , ε = -10-3, 2.0=
b
! , p = 2, and  13=Q  determined from pilot 
studies (Appendix A, Table A2).  These simulations were carried out for each value of 
the vigilance baseline parameter 
a
!  in the set {0.81, 0.83,…, 0.99}.  The vigilance 
baseline that resulted in the best performance on the validation set was chosen for each 
 Positions 
Given a 
Binary 
Representation 
Positions 
Given an 
Amino Acid 
Space 
Representation 
 
Validation 
Sets Test Sets 
NFV PAR AAPAR 0.99 0.82 0.81 
SQV PAR Positions with OPCD>1% 0.89 0.78 0.83 
IDV PAR Positions with OPCD>1% 0.89 0.83 0.82 
RTV PAR None 0.95 0.86 0.85 
APV All (1-99) 
Three Positions 
with Highest 
OPCD  
0.99 0.76 0.76 
LPV PAR  
Positions with 
OPCD>1% 0.93 0.85 0.87 
ATV PAR All 0.95 0.82 0.75 
Table 7. Representation and vigilance baseline (
a
! ) leading to the highest 
correlation coefficient on the validation sets for each of the seven protease 
inhibitors 
For each drug, the representation and vigilance baseline value (column four) that 
lead to the best network performance on the validation sets (Figure 6) are shown.  
Each representation involves a choice of positions in the protease gene to be given 
a binary representation (column two), and a choice of positions to be given an 
Amino Acid Space representation (column three).  Positions contained in the 
intersection of these sets are given an Amino Acid Space representation.  The 
correlation coefficients between the predicted and actual Resistance Factors of the 
protease genes in the validation and test sets are shown in columns five and six.  
Scatter plots of network predictions on the test sets are shown in Figure 6. 
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drug and representation.  In all, the simulations involved the training and testing of 
7x15x5x5x10 = 26,250 Analog ARTMAP neural networks.  
 Table 7 shows the representations and corresponding vigilance baseline values 
that led to the best correlation coefficients on the validation sets.  Figure 6 and the 
rightmost column of Table 7 show the results of applying these representation schemes 
and parameter values to the test set. 
 
8.1 Analysis:  Novel Mutations Associated with Protease Inhibitor Resistance  
 
  The application of Analog ARTMAP to protease inhibitor data provides a means 
for estimating drug resistance of viral subtypes containing novel protease gene sequences.  
In so doing, it identifies protease gene locations where mutations affect resistance.  The 
feature selection results shown in Figure 4 and Table 3 demonstrate the ability of these 
techniques to identify positions in the gene that are known to contribute to resistance, 
without the incorporation of prior knowledge into the system.  At the same time, several 
positions not previously associated with resistance are identified.  Position 35, for 
example, is strongly implicated for all seven protease inhibitors.  Positions 62, 37, and 77 
(77 has been associated with resistance only to Nelfinavir) are also implicated for all of 
the protease inhibitors.  These four positions have the highest Analog ARTMAP feature 
selection ∆ values out of all the positions not previously associated with resistance for all 
of the protease inhibitors except ATV.  The low mutual information between mutations at  
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these positions and Resistance Factors (Figures 3a and 3b) indicates that these are likely 
to be accessory mutations, contributing to resistance indirectly through interactions with 
mutations at other locations. 
 
8.2 Analysis:  Novel Mutations Associated with Hypersusceptibility 
 
 These methods also identify positions in the protease gene with amino acid-
specific contributions to protease inhibitor resistance.  Table 7 lists the representations 
that led to the best network performance on the validation sets.  For Nelfinavir (NFV) the 
highest correlation between predictions and target RFs occurs when an Amino Acid 
Space representation is given to the positions 33, 46, 47, 50, 54, 63, 71, 82, 88, and 93.  
These are precisely the positions that have previously been observed to make differential 
contributions to resistance depending on the specific amino acids comprising the 
mutations [2].  Thus for NFV, the methods corroborate published observations. 
For Saquinavir (SQV), the best network performance occurs when the positions 
with OPCD scores greater than one percent, i.e., 33, 43, 71, and 82 (Table 6), are given 
an Amino Acid Space representation.  Of these, position 43 has not previously been 
observed to make an amino acid-specific contribution to resistance.  Table 8 catalogs the 
23 sequences with mutations at position 43 for which Resistance Factors to SQV are 
present in the data.  For each of the four observed mutations K43T (a mutation at position 
43 in which the amino acid K (Lysine) present in the wild-type is replaced with amino 
acid T (Threonine)), K43N, K43E, and K43R, the number of sequences containing the   
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SQV Resistance to Sequences Containing Mutations at Position 43 
Mutation K43T K43N K43E K43R 
# Sequences 12 2 1 8 
Mean RF 57.3 0.8 1.5 14.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
IDV Resistance to Sequences Containing Mutations at Position 12 
Mutation T12A T12S T12P T12D T12N 
# Sequences 15 18 15 2 2 
Mean RF 3.0 1.0 11.7 10.5 11.8 
Mutation T12E T12I T12M T12K T12R 
# Sequences 1 4 1 4 1 
Mean RF 3.7 9.0 1.0 3.7 2.8 
IDV Resistance to Sequences Containing Mutations at Position 36 
Mutation M36V M36L M36I 
# Sequences 11 8 189 
Mean RF 17.7 0.8 15.4 
Table 8. Saquinavir (SQV) resistance to sequences containing 
mutations at position 43. 
For each of the four mutations occurring at position 43 among sequences 
in the data set, the number of sequences containing the mutation and the 
mean Resistance Factor of these sequences to SQV are shown.  The 
mutation K43N is of particular interest because the mean RF to SQV of 
sequences containing this mutation is below one, suggesting that K43N 
may confer some degree of hypersusceptibility to SQV. 
Table 9. Indinavir (IDV) resistance to sequences containing mutations 
at position 12. 
For each of the 10 mutations occurring at position 12 among sequences 
in the data set, the number of sequences containing the mutation and the 
mean Resistance Factor of these sequences to IDV are shown.   
Table 10. Indinavir (IDV) resistance to sequences containing mutations at 
position 36. 
For each of the three mutations occurring at position 36 among sequences 
in the data set, the number of sequences containing the mutation and the 
mean Resistance Factor of these sequences to IDV are shown.  The 
mutation M36L is of particular interest because the mean RF to IDV of 
sequences containing this mutation is below one, suggesting that M36L 
may confer some degree of hypersusceptibility to IDV. 
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LPV Resistance to Sequences Containing Mutations at Position 72 
Mutation I72T I72V I72E I72L I72M I72F I72R 
# Sequences 22 20 6 4 6 1 2 
Mean RF 11.6 8.3 2.8 4.1 17.5 1.9 58 
 
 
 
 
IDV Resistance to Sequences Containing Mutations at Position 37 
Mutation N37A N37S N37C N37P N37D N37T 
# Sequences 6 35 7 2 83 14 
Mean RF 11.1 4.5 5.5 11.2 16.5 5.5 
Mutation N37E N37Q N37H N37K N37Y N37R 
# Sequences 13 2 4 1 2 1 
Mean RF 4.0 0.5 14.2 0.8 6.4 1.7 
APV Resistance to Sequences Containing Mutations at Position 72 
Mutation I72T I72V I72E I72L I72M I72K I72F I72R 
# Sequences 21 24 7 3 9 1 1 3 
Mean RF 1.8 4.3 2.7 2.7 3.3 22.3 1.9 8.9 
Table 11. Indinavir (IDV) resistance to sequences containing 
mutations at position 37. 
For each of the 12 mutations occurring at position 37 among 
sequences in the data set, the number of sequences containing the 
mutation and the mean Resistance Factor of these sequences to IDV 
are shown.  The mutations N37Q and N37K are of particular interest 
because the mean RFs to IDV of the sequences containing these 
mutations are below one, suggesting that these mutations may confer 
some degree of hypersusceptibility to IDV. 
Table 12. Amprenavir (APV) resistance to sequences containing 
mutations at position 72. 
For each of the eight mutations occurring at position 72 among 
sequences in the data set, the number of sequences containing the 
mutation and the mean Resistance Factor of these sequences to APV 
are shown.   
Table 13. Lopinavir (LPV) resistance to sequences containing 
mutations at position 72. 
For each of the seven mutations occurring at position 72 among 
sequences in the data set, the number of sequences containing the 
mutation and the mean Resistance Factor of these sequences to LPV 
are shown.   
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mutation is listed in the second row, and the mean Resistance Factor to SQV of those 
sequences is listed in the third row.  Of particular interest is the fact that the two 
sequences containing K43N have a mean Resistance Factor below one, despite the 
presence of mutations known to confer resistance to SQV such as L90M (Appendix B).  
This may indicate that K43N contributes some degree of hypersusceptibility (the 
condition of being less resistant to a drug than the wild-type) to SQV.   
 For Indinavir (IDV), the best network performance occurs when the positions 
with OPCD scores greater than one percent, i.e., 12, 36, 37, 63, 82, and 88 (Table 6), are 
given an Amino Acid Space representation.  Of these, positions 12, 36, and 37 have not 
previously been observed to make an amino acid-specific contribution to resistance.  
Tables 9, 10, and 11 catalog the sequences with mutations at these positions for which 
IDV Resistance Factors are present in the data.  There are three mutations that may be 
linked to IDV hypersusceptibility: M36L, N37Q, and N37K.  Appendix B lists the gene 
sequences containing these mutations and their Resistance Factors to IDV.   
For Amprenavir (APV), the best network performance occurs when an Amino 
Acid Space representation is given to the three positions with the highest OPCD scores, 
i.e., 50, 71, and 72 (Table 6).  Of these, position 72 has not previously been observed to 
make an amino acid-specific contribution to resistance.  Table 12 catalogs the 69 
sequences with mutations at position 72 for which Resistance Factors to APV are present 
in the data set.    
For Lopinavir (LPV), the best network performance occurs when the positions 
with OPCD scores greater than one percent, i.e., 54, 71, 72, and 82 (Table 6), are given 
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an Amino Acid Space representation. Of these, position 72 has not previously been 
observed to make an amino acid-specific contribution to resistance.  The 61 sequences 
with mutations at position 72 for which Resistance Factors to LPV are present in the data 
set are shown in Table 13.    
The hypersusceptibility of a viral strain to a specific drug is a particularly 
important situation because it implies that, for a patient infected with that strain, there 
exists a treatment option that could reasonably be expected to reduce viral load more 
effectively for that patient than it would for a patient infected with the wild-type virus.  
This analysis suggests experimental tests to determine the relationship between the 
mutation K43N and Saquinavir hypersusceptibility, and between the mutations M36L, 
N37Q, and N37K and Indinavir hypersusceptibility. 
Supplemental material including a Java based implementation of Analog 
ARTMAP, protease inhibitor resistance data sets, and Amino Acid Spaces generated 
from several BLOSUM and PAM protein scoring matrices are available at 
http://profusion.bu.edu/techlab/. 
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Appendix A: The Analog ARTMAP Algorithm 
 
A self-contained Analog ARTMAP algorithm is presented below.   
 
Analog ARTMAP Training (Winner-Take-All Coding) 
 
Tr. 1. Complement code the M-dimensional training set feature vectors a  to produce 
2M-dimensional input vectorsA . 
 
 ( ) ( )
MM
c
aaaaaaaa !!!=" 1,...,1,1,,...,,,
2121
A  so that M=A  
 
Tr. 2. Set initial values: 
 
 1=ijw  
0=kjW  
1=C  
 
Tr. 3. Select the first input vectorA , with associated K-dimensional analog output 
vector 
 
),...,,( 21 KOOO=O  
 
Tr. 4. Set initial weights for the newly committed F2 coding node Cj = : 
 
 Aw =
C
 
           OW =
C
 
 1=
C
c  
 
Tr. 5. Set vigilance 
a
! to its baseline value: 
  
 
aa
!! =   
  
 and reset the code: 
  
 0=y  
Tr. 6. Select the next input vector A  and its associated analog output vector O  (until 
the last training point is reached). 
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Tr. 7.  Calculate signals to the committed coding nodes :...1 Cj =  
 
( )( )jjj MT wwA !!+"= #1  
 
Tr. 8. Search order: Sort the committed coding nodes with MTj !> in order of jT  
values from maximum to minimum. 
 
Tr. 9. Search sequentially for a coding node J that meets both the bottom up and top 
down matching criteria as follows: 
 
  Tr. 9a. Bottom-up matching criterion: 
   
   
a
J
M
!"##
$
%
&&
'
( )wA
 
 
Tr. 9b. Top-down matching criterion: 
 
 
bkk
Fk
O !" #$
%
3
max  
 
 where the analog prediction is: 
 
 !
=
=
C
j
jjkk yW
1
"  
  
 here the predictions are made in winner-take-all mode, so that  
  
 
!"
!
#
$
%
=
=
Jjif
Jjif
y j
0
1
  
 
 and the prediction becomes: 
 
 Jk
C
j
jjkk WyW ==!
=1
"  
 
Tr. 9c. Match: If both matching criteria are met, go to step Tr. 11 (learning). 
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Tr. 9d. Mismatch: If either the top-down or bottom-up matching criteria are not 
met, raise vigilance: 
 
   !" +
#
=
M
J
a
wA
  
 
and continue searching through the committed nodes  (return to step Tr. 
9a.). 
 
Tr. 10. If the list of committed nodes is searched unsuccessfully for a match, add a new 
committed node by increasing C by 1, and return to step Tr. 4. 
 
Tr. 11. Learning: Update the F1 to F2 weights by: 
 
   ( )old
J
new
J
wAw !=  
 
 and update the F2 to F3 weights as follows: 
 
  first update the instance counting weight associated with F2 node J: 
 
  1+=
JJ
cc  
    
   so that the learning rate for node J becomes: 
 
   
J
J
c
1
=!  
   
 then update the weight: 
 
 ( ) J
old
kJkJ
old
kJ
new
kJ yWOWW ,,, !+= "  
  
 Return to step Tr. 5 (the next training point). 
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Analog ARTMAP Testing (Distributed Coding) 
 
Ts. 1. Complement code M-dimensional test set feature vectors a  to produce 2M-
dimensional input vectors A . 
 
Ts. 2. Select the next input vector A , with associated K-dimensional analog output 
vector 
 
),...,,( 21 KOOO=O  
 
Ts. 3. Reset the code: 
 
  0=y  
 
Ts. 4. Calculate signals to committed coding nodes Cj ...1= : 
 
 ( )( )jjj MT wwA !!+"= #1  
 
Ts. 5. Let the set of F2 nodes with supra-threshold activations be: 
  
 { }MTC !" " >#=$ |}...1{    
 
 and let the set of F2 nodes with maximal activation be: 
 
 
{ }
{ }Aw =!=
=!="
=#
#
#
#
jC
MTC
|}...1{
|}...1{'
 
 
Ts. 6. Calculate F2 node activations: 
 
Ts. 6a. Apply the Increased Gradient (IG) Content Addressable Memory (CAM) 
rule: 
 
   Ts. 6a. 1.  Point Box Case: 
 
    If !"#' , set: 
 
     
'
1
!
=
j
y  for each '!"j  
 
   Ts. 6a. 2.  Otherwise, if !="' , set: 
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!
"#
$
%
&
'
(
)
*
$
$
%
&
'
'
(
)
*
=
+ +
P
P
j
j
TM
TM
y
1
1
 for each !"j  
    
Ts. 6b. Apply the Q-max rule: 
  
   Let the set of F2 nodes with the Q highest activations be: 
 
   
!
"
#
$
%
&
=''()'*)+*=' QandyyC '',''',''|}...1{'' ' ,,, ,,   
  
   Then set the F2 nodes’ activations to: 
 
  
!
!
"
!!
#
$
%&
%'
=
(
%&
''
''0
''
jif
y
y
jif
y jj
)
)
 
 
Ts. 7. Calculate the distributed analog predictions: 
 
 !
=
=
C
j
jkjkd yW
1
,,
"  
 
Ts. 8.  Return to step Ts. 2. until the last test point is reached. 
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Figure A. Analog ARTMAP network architecture 
A schematic representation of the Analog ARTMAP architecture 
for learning maps from multidimensional vector valued inputs to 
analog, multidimensional outputs. 
 
j 
jkW
ij
w
3
F
2
F
1
F
bkk
Fk
O !" >#
$
3
max
Code reset if 
Feature  
vector A ( )Mi aaa ,...,...1
Net  
signal 
Net  
signal 
k
!
jT
jT
k
!
Analog output 
Vector O 
( )
Kk
OOO ,...,...
1
k
j 
i 
ac 
Analog output 
layer, zk 
Coding 
layer, yj 
Complement  
coded input  
layer, xi 
Maj !<"wA
Code reset if 
a 
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NOTATION 
 
DESCRIPTION 
i Input component index 
j Coding node index 
k Output vector dimension index 
M Number of input features 
K Number of output features 
a Feature vector (ai), 0 ≤  ai ≤ 1  
A Complement coded input vector: 
A ≡ (a,ac) 
O Analog output vector: 
(Ok) 
y Coding field activation pattern 
(CAM): 
(yj) 
J Chosen coding node (winner-take-
all) 
C Number of committed coding 
nodes 
cj Instance counting weight 
βj Category-specific learning rate 
Λ,Λ’ Committed node subsets 
Tj Signal from input field to coding 
node j 
σk Signal from coding field to output 
node k 
wj Coding node weight vector j: 
(wij) 
Wk Output weight vector k: 
(Wjk) 
ρa Vigilance variable 
^ Component-wise minimum (fuzzy 
intersection): (p ^ q)i ≡ min(pi,qi) 
•
 Vector size (L1-norm): |p| !"
i
i
p  
pc Vector complement: (pc)i ≡ 1-pi 
Table A1. Analog ARTMAP Notation 
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NAME PARA-
METER 
RANGE DEFAULT 
VALUE 
NOTES 
Signal rule 
parameter 
α (0,∞) 0.01 Α = 0+ 
maximizes 
code 
compression 
 
Match 
tracking 
ε (-1,1) -0.001 ε < 0 (MT-) 
codes 
inconsistent 
cases 
 
Baseline 
vigilance 
a
!  [0,1) 0 
a
! = 0  
maximizes 
code 
compression 
 
Output 
vigilance 
b
!  [0,∞) 0.2 
b
! → ∞ 
maximizes 
code 
compression.   
b
! !  [0,1) for 
classification  
 
Increased 
Gradient 
(IG) CAM 
rule power 
 
p (0,∞) 2 p → ∞  
system 
converges to 
WTA  
 
Q-max 
CAM rule 
parameter 
 
Q [1,2,…,∞) 13 Q = 1 system 
becomes 
WTA 
 
# training 
epochs 
 
E [1,2,…,∞) 1 E = 1 
simulates on-
line learning 
# voting 
systems 
V [1,2,…,∞) 5  
Table A2. Analog ARTMAP Parameters 
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Appendix B: Protease Genes Containing Mutations K43N, M36L, N37Q, or N37K 
 
  
Sequences containing K43N Resistance 
Factor to 
SQV 
L10I, R41K, K43N, K45R, M46I, L63P, A71V, G73S, V77I, V82T, 
I85V, L90M, I93L 
0.5 
M36I, R41K, K43N, K45R, I62V, L63P, A71T, V82A, L90M 1.0 
Sequences containing M36L Resistance 
Factor to 
IDV 
M36L, L63P, A71T, V77I 0.3 
K14R, I15V, K20T, V32I, M36L, I66F, A71V, T74I, V82I, I85V 
 
0.9 
L10I, I13V, E35D, M36L, R57K, L63P, A71T, I72M 
 
0.2 
T12S, I15V, L19I, V32I, L33F, M36L, L63P, A71V 
 
1.0 
L10F, D30N, L33F, E35D, M36L, N37C, R41K, R57K, D60E, I62V, 
L63Q, I64V, N88D 
0.7 
I13V, D30N, E35D, M36L, I62V, L63Q, I64V, T74S, N88D 
 
1.0 
L19T, M36L, R57K, L63P, I64V 
 
0.7 
M36L, L63P 
 
1.8 
 
Sequences containing N37Q Resistance 
Factor to 
IDV 
L19V, L33I, N37Q, P39S, R41K, I54M, L63P, V82I, I93L 
 
0.6 
E35D, N37Q, R57K, L63P 
 
0.3 
Sequence containing N37K Resistance 
Factor to 
IDV 
I15V, M36I, N37K, R41N, H69K 
 
0.8 
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